Cancer feature: cnaPANCAN395

ADSSL1 AHNAK2 AKT1 AMN ANKRD9 APOPT1 ASPG BAG5 BCL11B BEGAIN BRF1 BTBD6 C14orf177 C14orf180 C14orf2 C14orf64 C14orf79 C14orf80 CCDC85C CCNK CDC42BPB CDCA4 CEP170B CINP CKB CRIP1 CRIP1 CRIP2 CYP46A1 DEGS2 DIO3 DLK1 DYNC1H1 EIF5 EML1 EVL EXOC3L4 GPR132 HHIPL1 HSP90AA1 INF2 JAG2 KIF26A KLC1 MARK3 MOK MTA1 NUDT14 PACS2 PLD4 PPP1R13B PPP2R5C RCOR1 RD3L RP11-204N11.1 RP11-73M18.2 RP11-796G6.2 RTL1 SETD3 SIVA1 SLC25A29 SLC25A47 TDRD9 TECPR2 TEX22 TMEM179 TNFAIP2 TRAF3 TRMT61A VRK1 WARS WDR20 WDR25 XRCC3 YY1 ZBTB42 ZFYVE21 ZNF839

Known Driver Genes: AKT1

Copy number alternation: gain

Osimertinib

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer